Skip to main content
. 2019 Jun 7;5(1):e000917. doi: 10.1136/rmdopen-2019-000917

Figure 2.

Figure 2

Baseline predictors of (A) ASDAS Major Improvement and (B) ASAS40 at week 12 of open-label adalimumab therapy. ASDAS, Ankylosing Spondylitis Disease Activity Score; ASAS40, 40% improvement in Assessment of SpondyloArthritis international Society; BASFI, Bath Ankylosing Spondylitis Functional Index; HAQ-S, Health Assessment Questionnaire modified for the Spondyloarthropathies; HLA-B27, human leucocyte antigen B27; hs-CRP, high-sensitivity C reactive protein; SI, sacroiliac; SPARCC, Spondyloarthritis Research Consortium of Canada. *Mean of BASDAI questions 5 and 6.